Digital From static documents to strategic capability: The case for ... Protocol documentation will become protocol ingestion – an approach that’s automated, consistent, and intelligent.
Digital Fail fast is not a cultural problem. It is a capital allocat... Even modest improvements in early predictive resolution can materially shift portfolio economics.
R&D Making AI work where it matters, with Rob DiCicco Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.
R&D Agentic AI and the human element: Building trustworthy autom... The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.
R&D Results, reality, and recalibration: Unpacking AI hype at SC... SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.
R&D From complexity to cohesion: AI’s growing role in building s... AI is being used from protocol design to study start-up and through clinical trial closeout, reshaping the trial lifecycle.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
